ANP

ANTISENSE THERAPEUTICS LIMITED - Discussion

3.85% ! 2.5¢

Antisense Therapeutics Limited (ANP) is an Australia-based pharmaceutical drug discovery... Antisense Therapeutics Limited (ANP) is an Australia-based pharmaceutical drug discovery and development company. The Company is engaged in the research and development of antisense pharmaceuticals. The Company's product candidate, ATL1103, is an antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood. ATL1103 is in clinical development for acromegaly, diabetic retinopathy and diabetic nephropathy. The Company's product candidate, ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. The Company completed a Phase IIa efficacy and safety trial of ATL1102 in multiple sclerosis (MS) patients. The Company's product candidate, ATL1101, is an antisense inhibitor of insulin like growth factor 1 receptor (IGF-Ir). It is developing ATL1101 for the treatment of prostate cancer. It is also developing ATL1102 as an inhaled treatment for asthma.More